(Q36451422)

14 August 2017

1 reference

title

B cell-targeted therapy for rheumatoid arthritis: an update on the evidence (English)

1 reference

14 August 2017

1 reference

R John Looney

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

66

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

625-639

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666050-00004

14 August 2017

exact match

0 references

cites work

Modulation of dendritic cell maturation and function by B lymphocytes

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666050-00004

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

12 December 2020

Rituximab treatment results in impaired secondary humoral immune responsiveness.

1 reference

12 December 2020

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Use of intravenous immunoglobulin G (IVIG).

1 reference

12 December 2020

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Natural antibodies sustain differentiation and maturation of human dendritic cells

1 reference

12 December 2020

The immunopathology of joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

Auto-immune manifestations in Non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment of childhood autoimmune haemolytic anaemia with rituximab

1 reference

12 December 2020

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

12 December 2020

Down-regulation of CD20 on B cells upon CD40 activation

1 reference

12 December 2020

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

T cell activation in rheumatoid synovium is B cell dependent

1 reference

12 December 2020

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy.

1 reference

12 December 2020

Anticytokine therapy in rheumatoid arthritis

1 reference

12 December 2020

Lymphoid neogenesis in rheumatoid synovitis

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia

1 reference

12 December 2020

Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?

1 reference

12 December 2020

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

1 reference

12 December 2020

The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

1 reference

12 December 2020

Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes

1 reference

12 December 2020

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

1 reference

12 December 2020

Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma

1 reference

12 December 2020

B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

1 reference

12 December 2020

The B cell surface molecule B1 is functionally linked with B cell activation and differentiation

1 reference

12 December 2020

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

1 reference

12 December 2020

Do self-perpetuating B lymphocytes drive human autoimmune disease?

1 reference

12 December 2020

Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

1 reference

12 December 2020

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

1 reference

12 December 2020

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

1 reference

12 December 2020

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

1 reference

12 December 2020

Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis

1 reference

12 December 2020

Reciprocal regulation of polarized cytokine production by effector B and T cells

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial

1 reference

12 December 2020

Intravenous administration of human gamma-globulin

1 reference

12 December 2020

Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis

1 reference

12 December 2020

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

12 December 2020

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

12 December 2020

B cells regulate autoimmunity by provision of IL-10.

1 reference

12 December 2020

Improvement of refractory rheumatoid arthritis after depletion of B cells

1 reference

12 December 2020

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

12 December 2020

Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients

1 reference

12 December 2020

Rheumatoid factor revisited

1 reference

12 December 2020

The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

Neutropenia in patients treated with rituximab

1 reference

12 December 2020

Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor

1 reference

12 December 2020

10.2165/00003495-200666050-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1049545564

0 references

1 reference